4,4‐Diallyl curcumin bis(2,2‐hydroxymethyl)propanoate ameliorates nonalcoholic steatohepatitis in methionine‐choline‐deficient diet and Western diet mouse models

Abstract

AbstractNonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) that causes severe liver damage, fibrosis, and scarring. Despite its potential to progress to cirrhosis or hepatic failure, approved drugs or treatments are currently unavailable. We developed 4,4‐diallyl curcumin bis(2,2‐hydroxymethyl)propanoate, also known as 35e, which induces upregulation of mitochondrial proteins including carnitine palmitoyltransferase I (CPT‐I), carnitine palmitoyltransferase II, heat shock protein 60, and translocase of the outer mitochondrial membrane 20. Among these proteins, the upregulated expression of CPT‐I was most prominent. CPT‐I plays a crucial role in transporting carnitine across the mitochondrial inner membrane, thereby initiating mitochondrial β‐oxidation of fatty acids. Given recent research showing that CPT‐I activation could be a viable pathway for NASH treatment, we hypothesized that 35e could serve as a potential agent for treating NASH. The efficacy of 35e in treating NASH was evaluated in methionine‐ and choline‐deficient (MCD) diet‐ and Western diet (WD)‐induced models that mimic human NASH. In the MCD diet‐induced model, both short‐term (2 weeks) and long‐term (7 weeks) treatment with 35e effectively regulated elevated serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) concentrations and histological inflammation. However, the antisteatotic effect of 35e was obtained only in the short‐term treatment group. As a comparative compound in the MCD diet‐induced model, curcumin treatment did not produce significant regulatory effects on the liver triglyceride/total cholesterol, serum ALT/AST, or hepatic steatosis. In the WD‐induced model, 35e ameliorated hepatic steatosis and hepatic inflammation, while increasing serum AST and hepatic lipid content. A decrease in epididymal adipose tissue weight and serum free fatty acid concentration suggested that 35e may promote lipid metabolism or impede lipid accumulation. Overall, 35e displayed significant antilipid accumulation and antifibrotic effects in the two complementary mice models. The development of new curcumin derivatives with the ability to induce CPT‐I upregulation could further underscore their efficacy as anti‐NASH agents.